EUVIMEDEUVIMED entdecken
VergleichsstudieRandomisierte kontrollierte StudieOpen Access

Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma

Michiel S van der Heijden, Guru Sonpavde, Thomas Powles, Andrea Necchi, Mauricio Burotto, Michael Schenker, Juan Pablo Sade, Aristotelis Bamias, Philippe Beuzeboc, Jens Bedke, Jan Oldenburg, Gurkamal Chatta und 13 weitere

New England Journal of Medicine · 09.11.2023 · 389 (19) · 1778-1789

DOI: 10.1056/nejmoa2309863 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift New England Journal of Medicine, erschienen am 09.11.2023. Verfasst von Michiel S van der Heijden und 24 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam (M.S.H.); Medical Oncology, Genitourinary Section, Dana-Farber Cance…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Transitional Cell, Cisplatin, Gemcitabine. Die Arbeit wurde bisher 517-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Bristol-Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellCisplatinGemcitabineNivolumabUrinary Bladder NeoplasmsHumansAdministration, Intravenous

Substanzen

CisplatinGemcitabineNivolumab

Autor:innen und Institutionen

  • From the Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam (M.S.H.); Medical Oncology, Genitourinary Section, Dana-Farber Cancer Institute, Harvard Medical School, Boston (G.S.); the Department of…

Förderung

  • NCI NIH HHS
  • Bristol-Myers Squibb

Zitieren

APA

van der Heijden, M. S., Sonpavde, G., Powles, T., Necchi, A., Burotto, M., Schenker, M., Sade, J. P., Bamias, A., Beuzeboc, P., Bedke, J., Oldenburg, J., Chatta, G., Ürün, Y., Ye, D., He, Z., Valderrama, B. P., Ku, J. H., Tomita, Y., Filian, J., …, & CheckMate 901 Trial Investigators (2023). Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma. New England Journal of Medicine, 389(19), 1778-1789. https://doi.org/10.1056/nejmoa2309863

Vancouver

van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, et al. Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma. New England Journal of Medicine. 2023;389(19):1778-1789. doi:10.1056/nejmoa2309863

BibTeX
@article{vanderHeijden2023,
  author = {van der Heijden, Michiel S and Sonpavde, Guru and Powles, Thomas and Necchi, Andrea and Burotto, Mauricio and Schenker, Michael and Sade, Juan Pablo and Bamias, Aristotelis and Beuzeboc, Philippe and Bedke, Jens and Oldenburg, Jan and Chatta, Gurkamal and Ürün, Yüksel and Ye, Dingwei and He, Zhisong and Valderrama, Begoña P and Ku, Ja Hyeon and Tomita, Yoshihiko and Filian, Jeiry and Wang, Lily and Purcea, Daniela and Patel, Miraj Y and Nasroulah, Federico and Galsky, Matthew D and CheckMate 901 Trial Investigators, CheckMate 901 Trial Investigators},
  title = {Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {389},
  number = {19},
  pages = {1778--1789},
  doi = {10.1056/nejmoa2309863}
}
Kostenlos starten →